Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait

Rabeah Al-Temaimi 1, Kusum Kapila 2, Fahd R Al-Mulla 3, Issam M Francis 4, Salah Al-Waheeb 4, Bushra Al-Ayadhy 3

Affiliations

01 January 2016

-

doi: 10.4103/0970-9371.175476

Abstract

Context: Nonsmall cell lung carcinoma (NSCLC) is the most frequently diagnosed form of lung cancer in Kuwait. NSCLC samples from Kuwait have never been screened for epidermal growth factor receptor (EGFR) gene aberration, which is known to affect treatment options.

Aims: This study investigated the feasibility of using fine-needle aspiration (FNA) material for mutational screening, and whether common EGFR mutations are present in NSCLC samples from Kuwait.

Settings and design: Eighteen NSCLC samples from five Kuwaitis and 13 non-Kuwaitis were included in this study.

Materials and methods: DNA was extracted from FNA cell blocks and screened for EGFR gene mutations using peptide nucleic acid (PNA)-clamp assay, and EGFR gene amplification using fluorescent in situ hybridization (EGFR-FISH). EGFR protein expression was assessed using immunohistochemistry.

Results: Five EGFR mutations were detected in five non-Kuwaiti NSCLC patients (27.8%). EGFR gene amplification was evident in 10 samples (55.5%) by direct amplification or under the influence of chromosomal polysomy. Four samples had EGFR mutations and EGFR gene amplification, out of which only one sample had coexisting EGFR overexpression.

Conclusions: Given the evidence of EGFR gene alterations occurring in NSCLC patients in Kuwait, there is a need to incorporate EGFR gene mutational screen for NSCLC patients to implement its consequent use in patient treatment.

Keywords: Epidermal growth factor receptor (EGFR); fine-needle aspiration (FNA); lung adenocarcinoma; mutational screen; nonsmall cell lung carcinoma (NSCLC).

Similar articles

EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).

Reynolds JP, Tubbs RR, Minca EC, MacNamara S, Almeida FA, Ma PC, Pennell NA, Cicenia JC.Lung Cancer. 2014 Nov;86(2):158-63. doi: 10.1016/j.lungcan.2014.09.003. Epub 2014 Sep 22.PMID: 25263855

[Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].

Sun MH, Yang F, Shen L, Zhang L, Chen Y, Cai X, Zhu XL, Zhou XY.Zhonghua Bing Li Xue Za Zhi. 2011 Oct;40(10):655-9.PMID: 22321541 Chinese.

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.

Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC.Int J Cancer. 2006 Feb 15;118(4):963-9. doi: 10.1002/ijc.21458.PMID: 16152581

Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH, Lee CT, Jheon S, Sung SW, Chung JH.Lung Cancer. 2010 Jun;68(3):375-82. doi: 10.1016/j.lungcan.2009.07.014. Epub 2009 Aug 26.PMID: 19712993

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.

Zhang K, Yuan Q.J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.PMID: 28230005 Review.

Cited by

Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer.

Liu S, Yang H, Ge X, Su L, Zhang A, Liang L.Oncol Lett. 2016 Nov;12(5):3941-3943. doi: 10.3892/ol.2016.5171. Epub 2016 Sep 22.PMID: 27895753 Free PMC article.

Erratum: Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.

[No authors listed]J Cytol. 2016 Apr-Jun;33(2):113. doi: 10.4103/0970-9371.182541.PMID: 27279692 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–27. - PubMed
  2.  
    1. El-Basmy A. Profile of lung cancer in kuwait. Asian Pac J Cancer Prev. 2013;14:6181–4. - PubMed
  3.  
    1. Wu M, Wang B, Gil J, Sabo E, Miller L, Gan L, et al. p63 and TTF-1 immunostaining.A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003;119:696–702. - PubMed
  4.  
    1. Brega E, Brandao G. Non-small cell lung carcinoma biomarker testing: The pathologist's perspective. Front Oncol. 2014;4:182. - PMC - PubMed
  5.  
    1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst. 2013;105:595–605. - PubMed
  6.  
    1. Li N, Yang L, Ou W, Zhang L, Zhang SL, Wang SY. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer. PLoS One. 2014;9:e102777. - PMC - PubMed
  7.  
    1. Riess JW, Wakelee HA. Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances. Clin Adv Hematol Oncol. 2012;10:226–34. - PubMed
  8.  
    1. Paz-Ares L, Soulières D, Moecks J, Bara I, Mok T, Klughammer B. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med. 2014;18:1519–39. - PMC - PubMed
  9.  
    1. Bosso M, Al-Mulla F. Whole genome amplification of DNA extracted from FFPE tissues. Methods Mol Biol. 2011;724:161–80. - PubMed
  10.  
    1. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, et al. EGFR fluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer. J Clin Pathol. 2009;62:970–7. - PMC - PubMed
  11.  
    1. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 2008;52:797–805. - PubMed
  12.  
    1. Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, et al. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor — A novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res. 2011;17:7796–807. - PMC - PubMed
  13.  
    1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45. - PubMed
  14.  
    1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. Lancet Oncol. 2012;13:790–801. - PubMed
  15.  
    1. Garcia-Olivé I, Monsó E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J. 2010;35:391–5. - PubMed
  16.  
    1. Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: A multicenter study of 774 patients. Am J Respir Crit Care Med. 2012;185:1316–22. - PMC - PubMed
  17.  
    1. Dogan S, Shen R, Ang DC, Johnson ML, D’Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169–77. - PMC - PubMed
  18.  
    1. Fakhruddin N, Mahfouz R, Farhat F, Tfayli A, Abdelkhalik R, Jabbour M, et al. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population. Oncol Rep. 2014;32:2223–9. - PubMed
  19.  
    1. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500. - PubMed
  20.  
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39. - PubMed
  21.  
    1. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol. 2012;13:e23–31. - PubMed
  22.  
    1. Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular pathology of lung cancer: Key to personalized medicine. Mod Pathol. 2012;25:347–69. - PubMed
  23.  
    1. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014:e353–65. - PubMed
  24.  
    1. Sequist LV, Rolfe L, Allen AR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;373:578–9. - PubMed
  25.  
    1. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277:301–8. - PubMed
  26.  
    1. Gaber R, Watermann I, Kugler C, Reinmuth N, Huber RM, Schnabel PA, et al. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. Diagn Pathol. 2014;9:165. - PMC - PubMed
  27.  
    1. Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer. 2010;68:375–82. - PubMed
  28.  
    1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415–53. - PubMed

Page Navigation